Venous thromboembolism - rivaroxaban: review proposal - February 2012

Proposal to move guidance to the static list

As you may be aware the planned date for review of the above guidance is February 2012

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal. 

Since TA170 was published, NICE has published a clinical guideline CG92 ‘Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery’. Although the clinical guideline does not reproduce the wording of TA170 verbatim, the recommendation has been effectively incorporated in that rivaroxaban is included in the list of options for pharmacological VTE prophylaxis after surgery in both elective hip and elective knee replacement.

There is no new evidence to suggest that the recommendations of TA170 should change nor that any ongoing trials of rivaroxaban that might be expected lead to a change in the recommendations. There has been no relevant change to the price of rivaroxaban (it is now cheaper than it was at the time TA170 was developed).

Based on this information, it is proposed that the guidance is placed on the static list until a decision is made to update CG92.  The review decision date for the clinical guideline is January 2013. If it is decided that the clinical guideline should be updated, then a new proposal for TA170 (and the related guidance TA157) can be developed during the pre-scoping stages of that guideline.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance. 

Please see appendix A for a full list of the organisations we have contacted. 

February 2012

This page was last updated: 24 February 2012